详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology(Open Access)

97| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C

作者：

机构： [1]Guangdong Lung Cancer Institute, Medical Research Center, Cancer Center of Guangdong Provincial People's Hospital andGuangdong Academy of Medical Sciences, Guangzhou 510080, China [2]Affiliated Guangdong Provincial People's Hospital,South China Un iversity of Tech no logy, Guan gzhou 510630, China [3]Departme nt of Pathology, Peki ng Union Medical CollegeHospital, Chinese Academy of Medical Sciences, Beijing 100006, China [4]National Research Center for TranslationalMedicin巳 Shanghai, RuiJin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China [']LungTumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200240, China [6]Division ofRespiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210029, China [7]Department ofOncology,川in Cancer Hospital, Changchun 132002, China [8]Department of Pathology, National Cancer Center/CancerHospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100006, China [9]Department ofPathology, West China Hospital, Sichuan University, Chengdu 610065, China [10]Department of Pathology, ZhongshanHospital, Fudan University, Shanghai 200433, China [11]Department of Hematology, First Affiliated Hospital, Institute ofHematology, School of Medicine, Ji nan Un iversity, Guangzhou 519000, China [12]Laboratory of On cology, Affiliated Hospitalof the Academy of Military Medical Sciences, Beijing 100071, China [13]Department of Oncology, First Clinical College ofSouth China University of Technology/Guangdong Lung Cancer Institute, Guangzhou 510060, China [14]People's LiberationArmy Cancer Center of Bayi Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing 210046, China [15]Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 519000, China [16]Department of Pathology,Affiliated Hospital of the Academy of Military Medical Sciences, Beijing 100071, China [17]Department of Pathology, BeijingHospital, Beijing 100071, China [18]Department of Breast Cancer Pathology and Research Laboratory of Cancer, TianjinMedical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of CancerPrevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China [19]Department ofPathology, Jinling Hospital Nanjing University School of Medicine, Nanjing 210029, China [20]State Key Laboratory ofMolecular Oncology, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy ofMedical Sciences and Peking Union Medical College, Beijing 100006, China [21]Department of Respiratory Medicine, PekingUnion Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100006, China [22]Department of Oncology,West China Hospital, Sichuan University, Chengdu 610065, China [23]Guangdong Lung Cancer Institute, GuangdongProvincical Prople's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China [24]Department ofMedical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking UnionMedical College, Beijing 100006, China [25]Department of Thoracic Oncology, Fujian Cancer Hospital, Fujian MedicalUniversity Cancer Hospital, Fuzhou 350001, China [26]Department of Oncology, Affiliated Hospital of the Academy of MilitaryMedical Sciences, Beijing 100071, China [27]Department of Pathology, Shanghai Cancer Center, Fudan University, Shanghai200433, China [28]Center for Translational Medicine, Hangzhou First People's Hospital, Nanjing Medical University, Nanjing210029, China [29]State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, RuiJin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China [30]Department of Breast Cancer, Cancer Center,Guangdong Provincial People's Hospital, Guangzhou 510080, China [31]Department of Pathology, Shanghai PulmonaryHospital, Tongji University School of Medicine, Shanghai 200240, China [32]Department of Oncology, No. 113 Hospital ofPeople's Liberation Army, Ningbo 315040, China [^]Department of Medical Oncology, Sir Run Run Shaw Hospital, College ofMedicine, Zhejiang University, Hangzhou 310020, China [34]Department of Oncology, The First Affiliated Hospital of NanjingMedical University, Jiangsu Province Hospital, Nanjing 210029, China [35]Department of Oncology, Renji Hospital, ShanghaiJiao Tong University School of Medicine, Shanghai 200240, China [36]Department of Medical Oncology, The First Hospital ofChina Medical University, Shenyang 110016, China [37]Department of Oncology, Second Affiliated Hospital, School ofMedicine, Zhejiang University, Hangzhou 310020, China [38]Department of Oncology, Zhongshan Hospital, Fudan University,Shanghai 200433, China [39]Department of Colorectal, Sun Yat-sen University Cancer Center, Guangzhou 519000, China [40]Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai 200433, China [41]Department ofInternal Medicine, The Third Affiliated Hospital of Harbin Medical University, Harbin 150030, China [42]Department of MedicalOncology, Sun Yat-Sen University Cancer Center, Guangzhou 519000, China [43]Department of Gastrointestinal Oncology,Peking University Cancer Hospital and Institute, Beijing 100142, China

出处：

DOI：

ISSN：

关键词： Cancer Consensus Next-generation sequencing technology

摘要：

Next-generation sequencing (NGS) technology is capable of sequencing millions or billions of DNA molecules simultaneously. Therefore, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology (CSCO) and the China Actionable Genome Consortium (CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians, pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure (SOP), data analysis, report, and NGS platform certification and validation. Copyright © 2019 by Cancer Biology & Medicine.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区医学：研究与实验

最新[2023]版：

大类 | 2 区医学

小类 | 3 区医学：研究与实验 3 区肿瘤学

JCR分区：

出版当年[2019]版：

Q1 ONCOLOGY Q1 MEDICINE, RESEARCH & EXPERIMENTAL

最新[2023]版：

Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 ONCOLOGY

影响因子： 5.6 最新[2023版] 5.9 最新五年平均 5.432 出版当年[2019版] 0 出版当年五年平均 4.467 出版前一年[2018版] 4.248 出版后一年[2020版]

第一作者：

第一作者机构： [1]Guangdong Lung Cancer Institute, Medical Research Center, Cancer Center of Guangdong Provincial People's Hospital andGuangdong Academy of Medical Sciences, Guangzhou 510080, China [2]Affiliated Guangdong Provincial People's Hospital,South China Un iversity of Tech no logy, Guan gzhou 510630, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology(Open Access)

文献详情

相关文献